Tandem Investment Advisors Inc. Has $5.83 Million Stock Position in IDEXX Laboratories, Inc. $IDXX

Tandem Investment Advisors Inc. reduced its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.9% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,376 shares of the company’s stock after selling 1,009 shares during the quarter. Tandem Investment Advisors Inc.’s holdings in IDEXX Laboratories were worth $5,830,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in IDXX. Beacon Investment Advisory Services Inc. increased its position in IDEXX Laboratories by 11.9% in the 4th quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock valued at $42,588,000 after buying an additional 6,710 shares in the last quarter. Nordea Investment Management AB boosted its holdings in IDEXX Laboratories by 114.1% in the fourth quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after acquiring an additional 8,845 shares in the last quarter. Procyon Advisors LLC bought a new position in IDEXX Laboratories in the fourth quarter worth approximately $1,966,000. Diversified Trust Co. grew its stake in IDEXX Laboratories by 223.5% in the fourth quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock valued at $2,841,000 after acquiring an additional 2,901 shares during the period. Finally, Congress Asset Management Co. increased its holdings in shares of IDEXX Laboratories by 9,894.0% during the fourth quarter. Congress Asset Management Co. now owns 153,908 shares of the company’s stock valued at $104,123,000 after acquiring an additional 152,368 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $567.44 on Friday. The company has a market cap of $44.76 billion, a PE ratio of 41.78, a price-to-earnings-growth ratio of 3.10 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52 week low of $513.02 and a 52 week high of $769.98. The business has a 50 day moving average price of $554.49 and a 200-day moving average price of $599.94. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the company earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. UBS Group decreased their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Stifel Nicolaus lowered their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Tuesday. Finally, Citigroup began coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective on the stock. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.